Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Drug Discov Today ; 24(1): 37-41, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30196006

RESUMEN

Thiopurine drugs continue to be a cornerstone of inflammatory bowel disease (IBD) treatment. Thiopurines are economical compared with many newer medical treatments for IBD, other chronic inflammatory diseases and leukaemia, although they are not without their shortcomings. These include a slow-onset therapeutic action and many adverse drug reactions. This feature article surveys published data, unpublished in vitro and in vivo experiments, as well as clinical experience, underpinning a rationale for bringing a novel thiopurine drug formulation to market. This formulation has a rapid action making it suitable for the induction and maintenance treatment of IBD and avoids most thiopurine-associated adverse reactions.


Asunto(s)
Inmunosupresores/administración & dosificación , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Tioguanina/administración & dosificación , Administración Rectal , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas , Humanos , Inmunosupresores/efectos adversos , Mucosa Intestinal/metabolismo , Tioguanina/efectos adversos
2.
Mol Genet Metab ; 119(1-2): 83-90, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27370710

RESUMEN

BACKGROUND: Miller syndrome (post-axial acrofacial dysostosis) arises from gene mutations for the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). Nonetheless, despite demonstrated loss of enzyme activity dihydroorotate (DHO) has not been shown to accumulate, but paradoxically urine orotate has been reported to be raised, confusing the metabolic diagnosis. METHODS: We analysed plasma and urine from a 4-year-old male Miller syndrome patient. DHODH mutations were determined by PCR and Sanger sequencing. Analysis of DHO and orotic acid (OA) in urine, plasma and blood-spot cards was performed using liquid chromatography-tandem mass spectrometry. In vitro stability of DHO in distilled water and control urine was assessed for up to 60h. The patient received a 3-month trial of oral uridine for behavioural problems. RESULTS: The patient had early liver complications that are atypical of Miller syndrome. DHODH genotyping demonstrated compound-heterozygosity for frameshift and missense mutations. DHO was grossly raised in urine and plasma, and was detectable in dried spots of blood and plasma. OA was raised in urine but undetectable in plasma. DHO did not spontaneously degrade to OA. Uridine therapy did not appear to resolve behavioural problems during treatment, but it lowered plasma DHO. CONCLUSION: This case with grossly raised plasma DHO represents the first biochemical confirmation of functional DHODH deficiency. DHO was also easily detectable in dried plasma and blood spots. We concluded that DHO oxidation to OA must occur enzymatically during renal secretion. This case resolved the biochemical conundrum in previous reports of Miller syndrome patients, and opened the possibility of rapid biochemical screening.


Asunto(s)
Anomalías Múltiples/genética , Deformidades Congénitas de las Extremidades/genética , Disostosis Mandibulofacial/genética , Micrognatismo/genética , Ácido Orótico/análogos & derivados , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/genética , Anomalías Múltiples/sangre , Anomalías Múltiples/fisiopatología , Anomalías Múltiples/orina , Preescolar , Dihidroorotato Deshidrogenasa , Genotipo , Humanos , Deformidades Congénitas de las Extremidades/sangre , Deformidades Congénitas de las Extremidades/fisiopatología , Deformidades Congénitas de las Extremidades/orina , Masculino , Disostosis Mandibulofacial/sangre , Disostosis Mandibulofacial/fisiopatología , Disostosis Mandibulofacial/orina , Micrognatismo/sangre , Micrognatismo/fisiopatología , Micrognatismo/orina , Mutación , Ácido Orótico/sangre , Ácido Orótico/orina , Oxidación-Reducción , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/sangre , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/orina , Uridina/sangre , Uridina/orina
3.
PLoS One ; 10(9): e0135047, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26325665

RESUMEN

INTRODUCTION: Xanthine oxidase (XO) is distributed in mammals largely in the liver and small intestine, but also is highly active in milk where it generates hydrogen peroxide (H2O2). Adult human saliva is low in hypoxanthine and xanthine, the substrates of XO, and high in the lactoperoxidase substrate thiocyanate, but saliva of neonates has not been examined. RESULTS: Median concentrations of hypoxanthine and xanthine in neonatal saliva (27 and 19 µM respectively) were ten-fold higher than in adult saliva (2.1 and 1.7 µM). Fresh breastmilk contained 27.3 ± 12.2 µM H2O2 but mixing baby saliva with breastmilk additionally generated >40 µM H2O2, sufficient to inhibit growth of the opportunistic pathogens Staphylococcus aureus and Salmonella spp. Oral peroxidase activity in neonatal saliva was variable but low (median 7 U/L, range 2-449) compared to adults (620 U/L, 48-1348), while peroxidase substrate thiocyanate in neonatal saliva was surprisingly high. Baby but not adult saliva also contained nucleosides and nucleobases that encouraged growth of the commensal bacteria Lactobacillus, but inhibited opportunistic pathogens; these nucleosides/bases may also promote growth of immature gut cells. Transition from neonatal to adult saliva pattern occurred during the weaning period. A survey of saliva from domesticated mammals revealed wide variation in nucleoside/base patterns. DISCUSSION AND CONCLUSION: During breast-feeding, baby saliva reacts with breastmilk to produce reactive oxygen species, while simultaneously providing growth-promoting nucleotide precursors. Milk thus plays more than a simply nutritional role in mammals, interacting with infant saliva to produce a potent combination of stimulatory and inhibitory metabolites that regulate early oral-and hence gut-microbiota. Consequently, milk-saliva mixing appears to represent unique biochemical synergism which boosts early innate immunity.


Asunto(s)
Inmunidad Innata , Microbiota , Leche Humana , Boca , Saliva , Adulto , Femenino , Recién Nacido , Masculino , Peróxido de Hidrógeno/análisis , Hipoxantina/análisis , Inmunidad Innata/inmunología , Inmunidad Innata/fisiología , Microbiota/inmunología , Leche Humana/química , Leche Humana/inmunología , Leche Humana/fisiología , Boca/inmunología , Boca/microbiología , Nucleótidos/análisis , Nucleótidos/metabolismo , Saliva/química , Saliva/inmunología , Tiocianatos/análisis , Xantina/análisis , Xantina Oxidasa/análisis , Humanos
4.
J Anal Toxicol ; 39(2): 140-3, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25342718

RESUMEN

In Australia, it is a requirement of workplace oral fluid (OF) drugs of abuse testing that drug recovery from collection devices be verified by an accredited laboratory. Recovery data are used in conjunction with collection volume imprecision data and uncertainty of measurement to provide an estimation of drug concentration in neat OF. The manufacturer's product information for the DCD5000 collection device indicates that the collection volume of the swab is 380 µL. Recovery data for the swab when used with the isopropanol provided by the manufacturer are not available. A series of experiments using fortified drug-free OF were performed to assess the collection volume imprecision of the Dräger DCD5000 swab and the recovery of drugs from the swab using isopropanol. The fortified OF was collected with the swabs (n = 16), and swabs were discharged into vials of isopropanol as per the manufacturer's instructions. The mean collection volume of the DCD5000 swab was 487 µL with an imprecision of 1.3%. Recovery of drug from the device ranged from 86 to 98% for drugs listed in the Australian OF workplace testing standard. Recovery of methadone, buprenorphine and norbuprenorphine ranged from 93 to 102%. Recovery of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene was 45%, suggesting that urine is more suitable sample if methadone therapy is being monitored. Overall, drug recovery from the device using isopropanol was acceptable when the increased collection volume of the swab was taken into account.


Asunto(s)
Detección de Abuso de Sustancias/instrumentación , 2-Propanol/análisis , Australia , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...